Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Isogenica, a company engaged in the discovery and optimisation of therapeutic and diagnostic peptides, proteins and antibodies using its proprietary technology, CIS display, has entered into a services agreement with Johnson & Johnson Pharmaceutical Research & Development (J&JPRD).
Subscribe to our email newsletter
Earlier in 2008, J&JPRD has got license to Isogenica’s CIS display technology, as successor in business to Centocor Research & Development, for application with the J&JPRD’s Centyrin scaffold protein platform.
With this current services deal, Isogenica has got the rights to conduct discovery work with the platform.
Isogenica CEO Kevin Matthews said they have been working hard to make CIS display an ‘industrialised’ molecular biology tool and it is great to see the progress we have made rewarded with this latest collaboration.